46. Fernandes, F. et al. Insect cells as a production platform of complex virus-like
particles. Expert Rev. Vaccines 12, 225–236 (2013).
47. Inﬂuenza vaccine strategies for broad global access. Available at https://path.
azureedge.net/media/documents/VAC_inﬂ_publ_rpt_10-07.pdf. Accessed August
2021.
48. European Medicines Agency. Assessment report. Supemtek. Procedure No.
EMEA/H/C/005159/0000. Available at https://www.ema.europa.eu/en/documents/
assessment-report/supemtek-epar-public-assessment-report_en.pdf. Accessed 17
February 2021.
49. Health Canada. Register of Innovative Drugs [Updated 15 April 2021]. Available
from https://www.canada.ca/en/health-canada/services/drugs-health-products/
drug-products/applications-submissions/register-innovative-drugs.html. Acces-
sed 19 April 2021.
50. Taubenberger, J. K. Inﬂuenza virus hemagglutinin cleavage into HA1, HA2: no
laughing matter. Proc. Natl Acad. Sci. USA 95, 9713–9715 (1998).
51. Stieneke-Gröber, A. et al. Inﬂuenza virus hemagglutinin with multibasic cleavage
site is activated by furin, a subtilisin-like endoprotease. EMBO J. 11, 2407–2414
(1992). PMC556715.
52. Chen, J. et al. Structure of the hemagglutinin precursor cleavage site, a deter-
minant of inﬂuenza pathogenicity and the origin of the labile conformation. Cell
95, 409–417 (1998).
53. Luczo, J. M. et al. Molecular pathogenesis of H5 highly pathogenic avian inﬂu-
enza: the role of the haemagglutinin cleavage site motif. Rev. Med Virol. 25,
406–430 (2015).
54. Boonstra, S. et al. Hemagglutinin-mediated membrane fusion: a biophysical
perspective. Annu Rev. Biophys. 47, 153–173 (2018).
55. McCraw, D. M., Gallagher, J. R. & Harris, A. K. Characterization of inﬂuenza vaccine
hemagglutinin complexes by cryo-electron microscopy and image analyses
reveals structural polymorphisms. Clin. Vaccin. Immunol. 23, 483–495 (2016).
56. Kost, T. A. & Condreay, J. P. Recombinant baculoviruses as expression vectors for
insect and mammalian cells. Curr. Opin. Biotechnol. 10, 428–433 (1999).
57. Webster, R. G., Brown, L. E. & Jackson, D. C. Changes in the antigenicity of the
hemagglutinin molecule of H3 inﬂuenza virus at acidic pH. Virology 126, 587–599
(1983).
58. Lee, P. S. & Wilson, I. A. Structural characterization of viral epitopes recognized by
broadly cross-reactive antibodies. Curr. Top. Microbiol. Immunol. 386, 323–341
(2015).
59. Turner, H. L. et al. Potent anti-inﬂuenza H7 human monoclonal antibody induces
separation of hemagglutinin receptor-binding head domains. PLoS Biol. 17,
e3000139 (2019).
60. Khurana, S. et al. Repeat vaccination reduces antibody afﬁnity maturation across
different inﬂuenza vaccine platforms in humans. Nat. Commun. 10, 3338 (2019).
61. Ekiert, D. C. et al. Antibody recognition of a highly conserved inﬂuenza virus
epitope. Science 324, 246–251 (2009).
62. Kallewaard, N. L. et al. Structure and function analysis of an antibody recognizing
ﬂ –